Technivie (ombitasvir, paritaprevir, and ritonavir)
What is Technivie?
UPDATE: AbbVie discontinued Technivie effective December 31, 2018.
On July 24, 2015 the U.S. Food and Drug Administration approved Technivie (ombitasvir, paritaprevir and ritonavir), which is a combination of ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor. Technivie is approved for use in combintation with ribavirin for the treatment of Hepatitis C genotype 4 infections in patients without scarring and poor liver function (cirrhosis). Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy in treating HCV genotype 4 without the need for interferon.
The active ingredients of Technivie are 12.5 mg ombitasvir, 75 mg paritaprevir, and 50 mg ritonavir.
Last Updated: December 2018
Bristol-Myers wins approval for 1st hepatitis C type 3 drug. http://www.washingtontimes.com/news/2015/jul/24/bristol-myers-wins-approval-for-1st-hepatitis-c-ty/, The Washington Times. Retrieved July 28, 2015.
Highlights of Prescribing Information - TECHNIVIE. http://rxabbvie.com/pdf/technivie_pi.pdf, AbbVie, Inc. Retrieved July 28, 2015.